• Premature infants (birth weight <1500g or gestational age <32 weeks)

• Infants with retinopathy of prematurity

• Children with special visual disabilities

In Taiwan, approximately 10% of the 140,000 newborns born annually are premature infants. Retinopathy of prematurity is a leading cause of blindness in infants and young children, with severity classified into five stages. Over 95% of stage 5 ROP patients will have no light perception without surgery. Since its establishment in 2006, the center has served thousands of premature infants, with over 2,600 consultations and screenings in the past decade, establishing itself as Taiwan's premier referral center for ROP care.

• Largest neonatal transfer and referral center in Northern Taiwan

• Most comprehensively specialized ophthalmology center nationwide

• First specialized children's visual care center in Taiwan

• First integrated long-term developmental care team for premature infants combining pediatric psychiatry and visual rehabilitation

• Leading global basic research and innovative clinical technology development

• Neonatal intensive care unit: 50 beds, 2,000 patients/year

• Infant ward: 54 beds, 2,500 patients/year

• Nursery: 40 beds, 2,000-2,500 patients/year

• Over 2,600 consultations and screenings in the past decade

• 500 eyes treated for retinopathy of prematurity

• Laser and intravitreal injection treatment (since 2010): 364 patients, 705 eyes

• Success rate for mild to moderate stages: 97.8%

• Vitrectomy surgery: 70 patients, 105 eyes, stage 4 success rate: 93.9%

• Pioneer in using intravitreal anti-VEGF injection for ROP treatment globally

• Development of advanced and innovative surgical techniques

• Development of artificial intelligence applications for ROP

• Standardized screening process established

• Close follow-up: Children without pathology screened every 2 weeks until retinal vessels reach zone III, then every 6 months

• Children with ROP require follow-up within 1 week

• Comprehensive multi-disciplinary team collaboration ensures high-quality care

• Disease explanation: Very satisfied 77.8%, Satisfied 22.2%

• Examination information and explanation: Very satisfied 72.2%, Satisfied 22.2%, Fair 5.6%

• Appointment scheduling and communication: Very satisfied 83.3%, Satisfied 16.7%

• Examination process and environment: Very satisfied 77.8%, Satisfied 22.2%

• Overall satisfaction: Very satisfied 72.2%, Satisfied 27.8%

• Overall satisfaction rate: 100% (Very satisfied + Satisfied)

• 2020 World's Top 2% Scientists

• 2023 Asia-Pacific Academy of Ophthalmology (APAO) Top 100

• Published landmark articles on anti-VEGF application for ROP assessment and management

• Leading publication quality among domestic medical centers

• Leading publication quality in Asia

• Publication quality exceeding international renowned eye centers

• Textbook authorship

• Published International Classification of Retinopathy of Prematurity (ICROP-3) treatment guidelines

• Participation in multiple multinational clinical trials

• International ROP learning center

• Trained 23 international retina fellows over the past decade (2012-2022)

• Severe stage 4 and 5 ROP patients requiring surgery in the US cost approximately 2 million NTD per vitrectomy; the center has performed 100 surgeries, saving at least 200 million NTD for the nation

• Successfully treating 100 patients who would otherwise require lifelong government support of approximately 5,000 NTD monthly until age 80 (total 4.4 million NTD per patient), the center has saved 444 million NTD for the nation